Yesterday, The New York Times  informed us that a small drug company called Allos is charging $30,000 a month for a cancer drug, Folotyn, that treats a rare and usually fatal form of cancer that strikes fewer that 6,000 American a year. It doesn’t cure the cancer, but merely slows it down; even with that, victims seldom survive more than a few months. “This drug is not a home run. It’s not even a double. It’s a single,” the Times quotes Dr. Brad S. Kahl, a lymphoma specialist at the University of Wisconsin, as saying. Continue reading →